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ABSTRACT  
Purpose 
Malignant pleural mesothelioma (MPM) has a high symptom burden and poor survival. Evidence from 
other cancer types suggests some benefit in health-related quality of life (HRQoL) with early specialist 
palliative care (SPC) integrated with oncological services, but the certainty of evidence is low. 
Methods 
We performed a multicentre, randomised, parallel group controlled trial comparing early referral to SPC 
versus standard care across 19 hospital sites in the United Kingdom and one large site in Western 
Australia. Participants had newly diagnosed MPM; main carers were additionally recruited. 
Intervention: review by SPC within three weeks of allocation and every four weeks throughout the 
study. HRQoL was assessed at baseline and every four weeks with the EORTC QLQ–C30 
questionnaire. Primary outcome: change in EORTC C30 Global Health Status (GHS) 12 weeks after 
randomisation. 
Results 
Between April 2014 and October 2016, 174 participants were randomised. There was no significant 
between group difference in HRQoL score at 12 weeks (mean difference 1.8 (95% CI: -4.9 to 8.5; 
p=0.59)). HRQoL did not differ at 24 weeks (mean difference -2.0 (95% CI: -8.6 to 4.6; p=0.54)). There 
was no difference in depression/anxiety scores at 12 or 24 weeks. In carers there was no difference in 
HRQoL or mood at 12 or 24 weeks, although there was a consistent preference for care, favouring the 
intervention arm. 
Conclusion 
There is no role for routine referral to SPC soon after diagnosis of MPM for patients who are cared for 
in centres with good access to SPC when required.  
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Trial Registration 
This study was registered with ISRCTN, number 18955704 
 
 
 
 
What is the key question? 
Does regular early specialist palliative care soon after the diagnosis of malignant pleural mesothelioma 
(MPM) lead an improved health related quality of life, when compared to standard care alone? 
 
What is the bottom line? 
Health related quality of life did not differ in patients with MPM receiving regular early SPC compared 
to standard care and there was no difference in anxiety/depression scores or survival. 
 
Why read on? 
This finding is in contrast to other studies of other cancer types and health care systems. Patients who 
are cared for in specialist centres with dedicated nurse specialists may be having their early holistic 
needs met.  
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INTRODUCTION 
 
Mesothelioma is a malignancy of mesothelial cells caused by exposure to asbestos fibres. It occurs most 
frequently in the pleura but may affect the peritoneum.1 2 Patients with mesothelioma have a high burden 
of symptoms3 4 and median survival is less than one year.5 The United Kingdom (UK) and Australia 
have some of the highest death rates in the world from mesothelioma.6 7 The global burden of 
mesothelioma largely reflects historic industrial utilization of asbestos throughout the last century. 
While many estimates suggest that developed countries are probably approaching the peak of 
mesothelioma incidence now, the continuing presence of asbestos within the built environment is likely 
to lead to continuing cases of mesothelioma for decades to come.  
 
The treatment of mesothelioma remains a significant challenge. Treatment includes combination 
chemotherapy with cisplatin (or carboplatin) and pemetrexed, which confers a 2-3 month improvement 
in survival.8 There is increasing interest in immunotherapy,9 however, to date there is no clear role for 
this; surgery remains highly controversial with no quality trial data to inform clinical practice.10  
 
Specialist palliative care (SPC) is the active, total care of patients with advanced, progressive malignant 
and non-malignant life-limiting illnesses,11 and those who care for them. SPC involves the management 
of physical symptoms and is also concerned with the provision of psychological, social and spiritual 
support. The fundamental aim of SPC is to contribute to achievement of the best quality of life possible 
for patients and their families at any time between diagnosis and death. A recent Cochrane review 
examining early palliative care in the context of advanced cancer12 included seven randomised  studies 
(five examining mixed cancer types, one pancreatic cancer and one non-small cell lung cancer 
(NSCLC)).13-19 The review concluded that there is evidence of a small increase in HRQoL with early 
integrated SPC provision, but the level of certainty of current evidence is low to very low. A more recent 
single centre randomised study of mixed advanced tumour types also reported a small to moderate 
improvement in HRQoL.20  
 
The aim of this study was to examine the effect of regular early SPC in combination with current 
standard care on HRQoL in patients with malignant pleural mesothelioma (MPM) and their carers 
compared to standard care alone. 
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METHODS 
 
Trial design  
We performed a multicentre, randomised, non-blinded, parallel group controlled trial comparing early 
referral to regular SPC versus standard care. The protocol has been published in detail previously.21 
 
Setting 
There were 19 recruiting secondary and tertiary hospital sites in the UK and one large tertiary site in 
Western Australia (WA).  
 
Participants 
The inclusion and exclusion criteria are listed in table 1. All potential participants were screened for 
eligibility at specialist thoracic cancer multidisciplinary team (MDT) meetings. Participants were 
encouraged to nominate a main carer for inclusion in the study, although those who did not were still 
eligible.  
 
Randomisation and blinding 
Following completion of the baseline assessments, eligible patients and their carers were randomised 
using minimisation with a random element in a 1:1 ratio between the intervention and control groups 
using an automated, centralised randomisation database, managed by the Oxford Respiratory Trials Unit 
(ORTU), Oxford, UK. Minimisation was performed according to: centre, plan for chemotherapy 
(yes/no), ECOG PS (0 or 1) and histological sub-type (epithelioid versus non-epithelioid (biphasic, 
sarcomatoid, not defined)). Due to the nature of the intervention it was not possible to blind participants 
or the immediate research team to the allocated intervention.  
 
Intervention 
Participants randomised to regular early SPC were reviewed by a palliative care physician within three 
weeks of allocation with carers encouraged to accompany the participants. SPC visits continued every 
four weeks (within +/- 7 days) for at least 24 weeks, until death or end of trial. To ensure a standard 
approach to SPC consultations across different centres, we used the Sheffield Profile for Assessment and 
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Referral to Care (SPARC) tool22 and the revised Edmonton Symptom Assessment System (ESAS-r)23 at 
initial consultations for all participants. Therefore, each SPC consultation included an assessment of the 
participant’s physical, psychological, social and spiritual needs, with provision of additional treatments 
and referral to additional support services as required.  
 
Control arm  
Control group participants received all appropriate, routinely provided treatment for MPM currently 
available in the UK and Australia, with no treatment withheld. All patients were discussed at a specialist 
MDT (with SPC representation) with a consensus for a treatment plan. There is usually initial frequent 
contact with the patients and carers, about symptom management, advice on potential legal 
compensation and preparation for chemotherapy. All recruiting centres had a dedicated thoracic cancer 
or mesothelioma specialist nurse as part of the clinical team during the study. The referral of participants 
in the control group to SPC was at the discretion of the medical team(s) based on clinical need.  
 
Outcomes 
Primary aim  
The primary aim was to determine if regular early SPC in newly diagnosed MPM patients resulted in 
improved HRQoL 12 weeks after randomisation, as compared to standard care. HRQoL was measured 
using the global health status (GHS) subscale of the European Organization for Research and Treatment 
of Cancer (EORTC) Quality of Life questionnaire Core 30 (QLQC30), with a higher score indicating a 
better HRQoL. This questionnaire has been validated in patients with MPM24 and used in other recent 
MPM studies.25 26 
 
Secondary aims  
The secondary aims included: participant HRQoL at 24 weeks (using the EORTC QLQC30); participant 
symptoms using the EORTC QLQ LC-13 lung cancer module supplement; participant mood at 12 and 
24 weeks and overall survival; primary caregiver’s HRQoL, mood and satisfaction with care at 12 and 
24 weeks, and additionally at 24 weeks following patient death.  
 
Caregiver HRQoL was assessed using the 1-week recall 36-Item Short Form Health Survey (SF-36v2). 
The FAMCARE-2 questionnaire has sound psychometric properties and measures family/carers 
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satisfaction with end-of-life care.27 Mood was assessed using the 12-item General Health Questionnaire 
(GHQ-12), a widely used measure for screening for psychiatric morbidity in adults.28 The study visit 
schedule is presented in the online supplement. 
 
Sample size 
With the assumption of a population mean of 55 and a common standard deviation of 22 in 
GHS/HRQoL for mesothelioma patients,24 we estimated that a sample size of 78 patients in each arm 
was required to detect a 10-point difference in the mean scores between the two groups, with a power of 
90% at a 5% two-sided significance level, assuming an association between baseline and follow-up GHS 
of  R2=0.25. With an estimated 10% dropout before the primary endpoint at 12 weeks, the required 
sample size was estimated to be 174 participants. 
 
Statistical methods 
The primary analysis of the 12-week primary outcome was based on the intention-to-treat approach (i.e. 
all patients analysed according to the group to which they were randomised) using a linear regression 
model adjusting for baseline (i.e. analysis of covariance (ANCOVA)), resulting in an adjusted mean 
difference in global health status score between randomised groups. We also performed the same linear 
regression additionally adjusting for the minimisation variables (centre, plan for chemotherapy, ECOG 
performance status and histological sub-type). We hypothesised that some data would be missing at 12 
weeks due to early mortality, and QoL may be associated with survival, so analysing QoL on its own 
may have led to bias. Therefore, we additionally used a joint modelling approach combining linear 
mixed effects models for repeated measurements and Cox models for censored survival outcomes.29 The 
model incorporated all follow-up measurements of the outcome (i.e. at 4, 8, 12, 16, 20 and 24 weeks) 
and survival time (with surviving patients censored at their 24-week visit or date of last known contact if 
they dropped out before the 24-week visit). Covariates of the mixed effects submodel were baseline 
measurement of the outcome, treatment group, measurement time point and a treatment group-
measurement time point interaction.  
 
For all patient reported secondary outcomes, ANCOVA models were used, as per the analysis of the 
primary outcome, as described above. Median survival times were obtained from the Kaplan–Meier 
product-limit estimate of the survivor function. Patients who were alive at the end of the trial were 
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censored at their last known date of contact. A Cox proportional hazards model was used to assess the 
effect of early SPC compared to standard care on survival with treatment group as the only covariate in 
the model.   
 
Per-protocol analysis consisted of those randomised participants who had at least one post baseline GHS 
score, additionally for those randomised to SPC: completed all scheduled monthly SPC visits within the 
specified +/- 7 day window prior to the primary time point. Pre-specified subgroup analyses comparing 
the EORTC C30 GHS at 12 and 24 weeks were performed on the following subgroups: 
neutrophil/lymphocyte ratio (NLR <5/≥5), International Association for Study of Lung Cancer 
Mesothelioma radiological stage (1 to 4),30 country of recruitment (UK/Australia), age at recruitment 
(<75/≥75 years), baseline ECOG PS (0/1), nominated carer at recruitment (yes/no). For each subgroup, a 
linear regression was performed for the GHS score adjusting for the baseline GHS score, treatment 
group, subgroup and the subgroup-treatment group interaction for week 12 and week 24 separately. 
Statistical analyses were performed using Stata version 15.1 (StataCorp, College Station, TX) at the 
Centre for Statistics in Medicine, University of Oxford. 
 
Ethics and governance 
Ethical approval for this study was granted by the National Research Ethics Service (NRES) Committee, 
London (Hampstead, UK), reference 12/LO/0078. This study was registered with ISRCTN, number 
18955704.  
 
RESULTS 
 
From April 2014 to October 2016 we assessed 687 potential participants for eligibility and 174 
participants were randomised and included in the intention to treat population (figure 1). At 12 weeks, 
157 (90.2%) participants were followed-up, and 135 (77.6%) at 24 weeks. There were 8 withdrawals 
and 31 deaths during the study period. Baseline characteristics were well balanced between the groups 
(table 2). The median follow-up (from randomisation to date of last known contact) was 41.1 
(interquartile range 25.1-61.9) weeks. 
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In addition, 145 main carers were recruited, 73 to the intervention group and 72 to the control group. At 
12 weeks after randomisation, 130 (89.7%) remained in the study, 109 (75.2%) remained at 24-weeks 
(online supplement figure 1). The characteristics of those participants contributing to the primary 
outcome at 12 weeks are presented in online supplement table 5; participants without the primary 
outcome data available where older and had more sarcomatoid containing histology.  
 
Adherence to the intervention 
In the intervention arm, 84 (96.6%) participants completed at least one SPC visit before 12 weeks with 
68 (78.2%) completing all three visits. 29 (33.3%) of the intervention group had at least 1 SPC visit 
falling outside of the +/- 7 day window. At 12 weeks after randomisation, 15 (17.2%) participants in the 
control arm had been referred to and seen by SPC. By week 24, 30 (34.5%) participants in the control 
arm had been referred to SPC. At 24 weeks after randomisation, 31 (17.8%) participants had died and 93 
(53.4%) had died at last point of contact (end of trial) with a median survival of 54.6 (95% CI 46.4 to 
72.9) weeks. 
 
Primary outcome 
There was no statistically significant between group difference in the mean score of the EORTC QLQ-
C30 GHS at 12 weeks after randomisation (table 3). 
 
Secondary outcomes 
The data for secondary analyses for patients is provided in table 3 and presented in figure 2. The 
association parameter from the joint model applied to the GHS score and survival data was -0.11 (95% 
CI: -0.16, -0.06, p<0.01), which implied a negative association between the GHS score and death times 
(i.e. the lower the score, the higher the chance of death). However, results remained consistent with the 
primary analysis i.e. the treatment effect estimated at each 4-week time point demonstrated no evidence 
of a significant difference between groups at any time. Symptom burden assessed using the EORTC 
QLQ LC-13 at 12 weeks after randomisation also had no significant between group differences (see 
online supplement).  
 
Survival 
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30 (17.2%) participants died within 24 weeks of randomisation. There was no mortality difference 
between the groups with a Cox proportional hazards regression analysis demonstrating a hazard ratio 
(HR) of 1.1 (95% CI 0.6, 2.3); p=0.74 and log rank test (chi-square (1) = 0.11; p=0.74). Throughout the 
duration of the study, 93 (53.4%) participants died. Again, there was no mortality difference between the 
groups with a Cox proportional hazards regression HR of 1.2 (95% CI 0.8, 1.7); p=0.50 and log rank test 
(chi-square (1) = 0.46; p=0.50: table 3 and online supplement figure 2).  
 
Outcomes for carers 
Data for the carer reported outcomes are presented in table 4. There was no evidence of a statistically 
significant difference in the physical or mental component measures of the SF-36 between treatment 
groups at any time point. The GHQ-12 score differed between the treatment groups at week 24, 
favouring a positive outcome on the intervention arm. FAMCARE-2 scores were significantly higher 
(better) in the intervention arm at week 12 and week 24, p-values derived using non-parametric 
comparison were in agreement with this conclusion. At 24-weeks post-bereavement the mean difference 
adjusted for baseline still favoured the intervention arm, although numbers were small in each arm.  
 
Protocol deviations and harms 
One participant was randomised to the intervention arm in error as they were ineligible and were 
withdrawn. One participant in the intervention arm was unable to attend the SPC clinic appointments. 
Nine SAEs were reported during the study in five patients; all SAEs related to clinical decline and none 
were related to the intervention.  
 
Pre-specified subgroup analyses 
There were no statistically significant between-group differences in the EORTC C30 GHS observed 
within any of the pre-specified subgroups (see online supplement).  
 
 
DISCUSSION 
 
The RESPECT-Meso trial demonstrates that for patients with MPM with good performance status, 
routine referral to SPC soon after diagnosis does not confer any benefit in HRQoL and/or mood. This is 
the largest randomised controlled trial to examine this question in patients with mesothelioma. This 
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study suggests strongly that current standard palliative management in the UK and Australia is 
adequately meeting the holistic needs of patients early in the disease trajectory of mesothelioma.  
 
We have considered if the study design or conduct may have led to a type II error, missing a real effect 
of the intervention. Dropout (from lost to follow up, withdrawal and death) before the primary outcome 
at 12 weeks after randomisation was as anticipated at 17 (9.8%) and data completeness for the primary 
outcome was good, thus, it is unlikely this study was underpowered. As anticipated in this pragmatic 
study, there was some dilution of effect from the intervention with 19 (21.8%) of the intervention group 
not completing all SPC visits and 15 (17.2%) of the standard care arm having received SPC review 
before the 12-week outcome. The primary outcome measure is a well validated and accepted measure 
for mesothelioma HRQoL and our baseline estimates of HRQoL were similar to two recent large 
randomised controlled trials in MPM25 26 suggesting validity of our findings. Finally, we have performed 
a post hoc analysis of those who died within 24 weeks of randomisation vs. those alive at 24 weeks; this 
demonstrated a lower baseline score in those who died, but no significant between group difference 
(mean GHS QLQ-C30 score (SD) early SPC vs. standard care: 38.9 (30.6) vs. 46.4 (21.4); p=0.25). 
Overall, we consider that the study result is a true negative.  
 
The results of this study appear to be different to other similar reports examining early SPC in differing 
cancer types.13-20 Aside from differing study designs, the RESPECT-Meso study has examined a 
different disease in a different healthcare system compared to other studies. It is also possible that our 
study has recruited participants too early in the disease trajectory for the intervention to be useful 
(although the post hoc analysis above does not support this supposition). The inclusion criteria of the 
study included the requirement for an ECOG performance status of 0 or 1 which means the study 
recruited a relatively well population. The inclusion of participants with a performance score of 2 would 
have led to a much higher drop out (by death) before the primary outcome, and the potential for the 
study being underpowered. Despite the requirement for a good performance status, at the time of 
randomisation 77.0% of participants reported dyspnoea and 57.4% chest pain. At least one cycle of 
chemotherapy was completed in 59.2% of participants, suggesting that approximately one third of the 
study population had contraindications and/or comorbidities precluding systemic cytotoxic therapy. The 
median survival of the whole study population was 54.6 weeks, suggesting that despite a good 
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performance status at recruitment, many participants were symptomatic at baseline and deteriorated 
quickly.  
 
The results for main carers are similar as for the participants. There is no demonstrable difference in 
QoL and an isolated signal of a lower anxiety/depression score at 24 weeks after randomisation, 
favouring the intervention arm. There is, however, a clear indicator of an increased overall satisfaction 
with care for the carers in the early regular SPC group. From the FAMCARE questionnaire, there was 
increased reported satisfaction with ‘SPC’s attention to patient’s symptoms’, ‘emotional support to 
family members’, ‘how effectively SPC manages the patient’s symptoms’, the ‘response to changes in 
symptoms’ and ‘emotional support provided to the patient by the SPC team’. SPC regards the patient as 
the centre of a family group, so that the assessment and management of carers’ needs is recognized as 
integral to patient care; this may in part explain the observed increased carer satisfaction. 
 
Rather than regular early SPC having little effect on HRQoL or mood, it is possible that the current 
provision of clinical care in the control arm is providing a good level of holistic cancer care. All 
recruiting centres in this study had senior specialist thoracic cancer and chemotherapy nurses. It is 
plausible therefore that in the early months after diagnosis, the level of physical, emotional and spiritual 
care provided to most patients with mesothelioma in these treating centres is meeting patients’ needs, 
however, this study has not specifically tested this supposition. SPC should, however, continue to be 
involved when patients’ pain, symptoms, psychological/spiritual or advance care planning needs are no 
longer met by their respiratory or oncological teams; that 34.5% of patients in the control arm had been 
referred to SPC by week 24 appears to confirm this. Future studies might include specific pain and 
symptom outcome measures and/or examine which patients, what levels and when in their disease 
trajectory patients will most benefit from referral to SPC. Before understanding further the possible 
role(s) of early SPC integrated into oncological care it may be useful to better understand and delineate 
the current aspects of general palliative care already being provided as standard care in many treating 
centres. In addition, the crucial aspect of direct and indirect healthcare associated costs for providers and 
individuals must be analysed when assessing the utility of a new intervention. Given the results of the 
primary and secondary outcomes in this study, the pre-specified formal healthcare economic evaluation 
was not performed as originally stated in the protocol.21 
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Potential limitations of this study include a high failure rate of screening (predominantly from refusal 
and not fitting eligibility criteria). Post-surgery and participants who had already started systemic 
chemotherapy where excluded as they were likely to have very different health needs and quality of life. 
The exclusion of ECOG PS 2 participants potentially reduces the generalizability of the study, although 
in the UK and Western Australia between 67-80% of MPM patients present with an ECOG PS of 0-1.5 31 
Furthermore, the uniformity of the SPC intervention provided across multiple sites may have varied 
after the initial standardized baseline assessment, but the nature of palliative care is inherently bespoke 
to the patients’ (and families’) needs. Finally, while this was a multicentre study, 20.7% of recruitment 
was from a tertiary cancer centre for Western Australia, however, pre-specified sub-group analysis did 
not demonstrate any difference in HRQoL measurements between the Australian and UK sites and the 
provision of both standard and SPC care is similar between the UK and Australia. 
 
In conclusion, our data do not support the routine early referral of good performance status patients with 
newly diagnosed malignant pleural mesothelioma to SPC services, provided there is specialist follow up 
and good access to SPC when required. The current practice of referral to SPC based on clinical 
judgment of the treating physician and MDT from symptom burden and perceived need should continue. 
The perceived increased carer satisfaction with SPC teams is noteworthy, but this finding alone is 
unlikely to influence widespread provision of healthcare services in this context.   
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Tables  
 
Table 1. Inclusion and exclusion criteria for the RESPECT-Meso study 
Inclusion criteria 
histological or cytological confirmation of MPM 
European Cooperative Oncology Group (ECOG) Performance Score (PS) of 0 to 1 (0 indicating the patient is 
asymptomatic, 1 indicating some symptoms but ambulatory) 
diagnosis of MPM received within the last six weeks 
participants were able to provide informed consent in English and comply with trial procedures 
 
Exclusion criteria 
another known malignancy within five years (excluding localised squamous cell carcinoma of the skin, cervical 
intraepithelial neoplasia, grade III and low-grade prostate cancer (Gleason score <5, with no metastases)) 
significant morbidity which might unduly confound or influence HRQoL 
a symptom burden sufficient to require referral to SPC at the time of diagnosis 
concurrent, or less than three months since participation in another clinical trial that may affect HRQoL 
surgery for MPM including cytoreductive, tumour de-bulking, radical decortication or extrapleural pneumonectomy 
(Video Assisted Thoracoscopic Surgery (VATS) or ‘mini’ thoracotomy for pleurodesis and diagnosis attempts were 
permissible) 
chemotherapy for MPM initiated prior to consent 
a significant history of depression/anxiety/psychiatric illness requiring specialist hospital care within the last twelve 
months 
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Table 2. Baseline characteristics of study participants.  
 Early Specialist Palliative Care 
(n=87) 
Standard Care (n=87)  
 n=  n=  
Age median (LQ, UQ) 87 72.1 (66.7, 77.7) 87 72.8 (69.0, 78.9) 
Gender Male (%)  87 67 (77.0) 87 72 (82.8) 
Neutrophil to Lymphocyte Ratio Median 
(LQ, UQ)  
87  3.6 (2.7, 5.3) 86 4.1 (2.9, 7.4) 
Co-morbidities Yes (%) 
Underlying respiratory disease  87 12 (13.8) 87 9 (10.3) 
Cardiac failure 87 0 (0.0) 87 0 (0.0) 
Ischaemic heart disease 87 8 (9.2) 87 9 (10.3) 
Chronic renal impairment 87 2 (2.3) 87 1 (1.2) 
Diabetes 87 9 (10.3) 87 7 (8.1) 
Other  87 19 (21.8) 87 28 (32.2) 
Designated carer Yes (%) 87 73 (83.9) 87 72 (82.8) 
Previous treatment received Yes (%) 
Cordotomy 87 1 (1.2) 87 0 (0.0) 
Nerve block  87 0 (0.0) 87 0 (0.0) 
Radiotherapy  87 1 (1.2) 87 1 (1.2) 
Symptoms at baseline Yes (%) 
Suffers pain  87 54 (62.1) 87 46 (52.9) 
Pain due to mesothelioma  54 27 (50.0) 46 28 (60.9) 
Analgesia use  87 55 (63.2) 87 56 (64.4) 
Breathlessness  77 26 (33.8) 73 25 (34.2) 
Fatigue 76 29 (38.2) 72 27 (37.5) 
Pleural procedures Yes (%) 87 67 (77.0) 87 69 (79.3) 
Therapeutic tap 67 26 (38.8) 69 28 (40.6) 
Chest Drain 67 19 (28.4) 69 20 (29.0) 
Chest Drain and pleurodesis 67 21 (31.3) 69 16 (23.2) 
Indwelling pleural catheter 67 7 (10.4) 69 12 (17.4) 
Medical thoracoscopy  67 26 (38.8) 69 27 (39.1) 
Video assisted thoracoscopic 
surgery (VATS) 
67 28 (41.8) 69 21 (30.4) 
Mini thoracotomy 67 0 (0.0) 69 1 (1.4) 
IASLC radiological stage  
1 
2 
3 
4 
45  
15 (31.3) 
3 (6.3) 
16 (33.3) 
14 (29.2) 
53  
20 (36.4) 
8 (14.5) 
16 (29.1) 
11 (20.0) 
Minimisation factors     
Plan for chemotherapy Yes (%) 87 47 (54.0) 86 45 (52.3) 
ECOG performance status 
0 
1  
87  
34 (39.1) 
53 (60.9) 
87  
32 (36.8) 
55 (63.2) 
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 Early Specialist Palliative Care 
(n=87) 
Standard Care (n=87)  
 n=  n=  
Histological subtype  
Non-Epithelioid/Epithelioid  
(% Non-Epithelioid/Epithelioid) 
87 19/68 
(21.8/78.2) 
87 19/68 
(21.8/78.2) 
UQ = upper quartile; LQ = lower quartile; IALSC = International Association for the Study of Lung Cancer 
 
 
 
 
 
Table 3. Participant-reported outcome measures at 12 and 24 weeks.  
 Early Specialist palliative 
care  
Control Mean Difference 
adjusted for 
baseline (95% CI) 
p value 
n= Mean score (SD) n= Mean score (SD)   
EORTC QLQ-C30 GHS  
at 12 weeks (primary 
outcome) 
75 60.2 (23.6) 73 59.5 (21.2) 1.8 (-4.9 to 8.5) 0.59 
at 24 weeks  60 61.3 (20.7) 65 63.7 (19.8) -2.0 (-8.6 to 4.6) 0.54 
Using a linear regression 
model, adjusting for 
minimisation variables, at 12 
weeks 
75 60.2 (23.6) 72 59.6 (21.3) 2.2 (-4.8 to 9.3) 0.50 
Using mixed effects linear 
regression modelling at 12 
weeks 
75 60.2 (23.6) 73 59.6 (21.3) 2.2 (-4.8 to 9.3) 0.50 
Per protocol analysis (12 
weeks) 
41 59.1 (21.2) 72 60.2 (22.8) 1.6 (-6.3 to 9.6) 0.68 
Depression / anxiety: GHQ-12 scores 
12 weeks  74 2.2 (3.0) 69 2.6 (3.2) -0.6 (-1.5 to 0.4) 0.23 
24 weeks 57 1.8 (2.5) 64 2.1 (2.5) -0.4 (-1.2 to 0.4) 0.27 
 
Median survival (95% CI) 87 50.0 (42.4 to 
69.0) 
 
87 54.7 (46.4 to 
85.4)  
 0.50* 
*log rank test. SD = standard deviation; CI = confidence interval 
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Table 4. Carer reported outcome measures at 12 and 24 weeks after randomisation and 24 weeks post-bereavement. 
  
 Early Specialist palliative 
care  
Control Mean Difference 
adjusted for baseline 
(95% CI) 
p value 
n= Mean score (SD) n= Mean score (SD) 
SF-36: Physical component       
12 weeks 59 53.4 (9.7) 49 51.8 (9.2) 1.8 (-0.7 to 4.3) 0.16 
24 weeks 45 52.6 (10.0) 42 50.7 (8.8) 1.3 (-1.7 to 4.4) 0.37 
24 weeks post bereavement 14 51.8 (11.3) 14 54.2 (7.5) -3.6 (-8.9 to 1.7) 0.15 
SF-36: Mental component       
12 weeks 59 43.7 (12.4) 49 45.1 (10.6) 0.5 (-2.8 to 3.9) 0.75 
24 weeks 45 46.3 (9.8) 42 45.7 (11.8) 1.0 (-3.0 to 4.9) 0.63 
24 weeks post bereavement 14 41.1 (11.7) 14 42.9 (11.7) 0.4 (-6.8 to 7.6) 0.90 
GHQ-12       
12 weeks 63 3.6 (3.4) 57 3.4 (3.1) -0.3 (-1.2 to 0.6) 0.50 
24 weeks 44 2.5 (3.3) 51 3.7 (3.8) -1.7 (-2.9 to -0.4) 0.01 
24 weeks post bereavement 16 4.2 (3.7) 17 4.1 (4.1) 0.4 (-1.7 to 2.5) 0.67 
FAMCARE-2       
12 weeks 63 78.5 (8.9) 51 74.5 (9.0) 4.1 (0.7 to 7.4) 0.02 
24 weeks 45 79.5 (6.8) 43 73.3 (11.4) 6.1 (2.1 to 10.1) 0.003 
24 weeks post bereavement 16 78.3 (7.6) 16 69.9 (15.9) 8.5 (-0.5 to 17.5) 0.05* 
SD= standard deviation; CI = confidence intervals. * Mann-Whitney U-test p=0.12 
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FIGURES 
 
Figure 1. CONSORT study diagram 
 
 
Figure 2. Mean ± 95% CI of the mean global health status score (raw values) at all time points by 
treatment group. N(SC)=no. of available GHS scores in the standard care arm; N(SPC)=no. of available 
GHS scores in the specialist palliative care (SPC) arm 
 
 
 
 
 
 
  
 
Assessed for eligibility (n=687) 
513 excluded 
170 declined to participate 
344 did not meet inclusion criteria 
• 96 ECOG PS >2 
• 39 referral to SPC at time of diagnosis 
• 31 known malignancy within last 5 years 
• 35 diagnosis of mesothelioma >6 weeks 
• 40 participation in another trial 
• 11 commenced chemotherapy prior to 
consent 
• 14 significant other comorbidity 
• 6 significant psychological comorbidity 
• 22 out of catchment area 
• 42 Not malignant pleural mesothelioma 
• 5 died during screening 
• 2 other (non-English speaking; not stated) 
Analysed (n=75) 
♦ Excluded from analysis (n=5) Did not attend 
12 week visit (n=3); insufficient data from 
EORTC C30 (n=2) 
Lost to follow-up (n= 7) 2 withdrew, 5 died 
Discontinued intervention (unable to attend 
clinic appointments) (n=3) 
Allocated to intervention (n=87) 
♦ Received allocated intervention (n=83) 
♦ Did not receive allocated intervention 
(ineligible) (n=1)  
 
Lost to follow-up (n=10) 4 withdrew, 6 died. 
Allocated to control (n=87) 
 
Analysed  (n=73) 
♦ Excluded from analysis (n=4) Did not attend 
12 week visit (n=3); insufficient data from 
EORTC C30 (n=1) 
Allocation 
Analysis 
Follow-Up 
Enrollment 
RESPECT-Meso CONSORT Flow Diagram 
Randomised (n=174) 
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